se of Anti-IL-17 in patients with the severe acute respiratory syndrome (SARS) associated with Covid-19

Pesquisador0 个研究点开始时间: 2020年7月6日最近更新: 2023年5月29日

适应症

试验速览

暂无简介。

•Adult patients (age > 18 years); admitted to the Hospital Risoleta Tolentino Neves (HRTN) with SARS-CoV-2 infection confirmed by RT-PCR of oropharyngeal swab or tracheal aspirate; and evolve with fever (at least one measure > 38º C in the last 24h) and severe acute respiratory syndrome (SARS) according to the Brazilian Ministry of Health definition (dyspnea / respiratory discomfort OR persistent chest pressure OR O2 saturation less than 95% in room air OR bluish coloration of the lips or face).

•Functional classes III and IV of congestive heart failure (CHF) or chronic obstructive pulmonary disease (COPD); stages 4 and 5 of chronic kidney disease (GFR <30 mL/min); diabetic ketoacidosis; known history of HIV/AIDS infection or chronic or acute HBV or HCV infection; uncontrolled bacterial or fungal co-infections (defined by hemodynamic instability, prior 48h of antimicrobial covering, or at the discretion of the study's medical coordinator); active tuberculosis (TB) infection; history of malignancy in the last year; current users (or in the last 15 days) of immunosuppressants (synthetic or biologic) or corticosteroids (in doses equivalent to or greater than 10mg of prednisone per day); neutrophils count <1000/mm3; pregnancy or breastfeeding (pregnancy test will be performed during the screening period, before the inclusion, in all women of childbearing potential).

发起方

Pesquisador